Chromatin-Accessible miRNA Regulons Driving Thyroid Tumorigenesis and Progression

Area of Science:

• Oncology
• Molecular Diagnostics
• Genomics

Background:

• Papillary thyroid cancer has significant rates of lymph node metastasis (approx. 50%) and recurrence (approx. 20%).
• Omics-based medicine offers predictive biomarkers for tumor progression and clinical outcomes.
• Accurate risk stratification is crucial for tailoring patient treatment plans.

Purpose of the Study:

• To develop a noninvasive, omics-driven blood test for accurate risk stratification of papillary thyroid cancer.
• To identify an epigenetic prognostic panel of microRNAs (miRNAs) for predicting tumor progression.
• To create a predictive risk nomogram for clinical application.

Main Methods:

• RNA sequencing and miRNA analysis of The Cancer Genome Atlas and Gene Expression Omnibus datasets.
• Validation using sequencing and real-time polymerase chain reaction on thyroid tissues and blood samples.
• Development of a clustered regularly interspaced short palindromic repeats (CRISPR)-fluorescent detection system miRNA assay.

Main Results:

• A miRNA panel (miR-146b-5p and miR-221-3p) was identified in tissue and blood, associated with aggressive features.
• The miRNA risk score and nomogram demonstrated high accuracy in predicting lymph node metastases and recurrence.
• CRISPR-based miRNA assays showed upregulation in the blood of cancer patients, outperforming existing risk stratification methods.

Conclusions:

• CRISPR-based detection of miR-146b and miR-221 in blood is a reliable, noninvasive tool for thyroid cancer prognostication.
• This assay has the potential to significantly impact the clinical management of thyroid cancer patients.
• The developed blood test enables real-time assessment and aids in personalized treatment strategies.